Document Detail

Permanent coronary artery occlusion: cardiovascular MR imaging is platform for percutaneous transendocardial delivery and assessment of gene therapy in canine model.
MedLine Citation:
PMID:  18780824     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To provide evidence that vascular endothelial growth factor (VEGF) genes delivered transendocardially with magnetic resonance (MR) imaging guidance may neovascularize or improve vascular recruitment in occlusive infarction.
MATERIALS AND METHODS: All experimental procedures received approval from the institutional committee on animal research. Dogs with permanent coronary artery occlusion were imaged twice (3 days after occlusion for assessment of acute infarction; a mean of 50 days after occlusion +/- 3 [standard error of the mean] for assessment of chronic infarction). A mixture of plasmid VEGF and plasmid LacZ (n = 6, treated animals) or plasmid LacZ and sprodiamide (n = 6, placebo control animals) was delivered to four sites. MR fluoroscopy was used to target and monitor delivery of genes. The effectiveness of this delivery approach was determined by using MR imaging methods to assess perfusion, left ventricular (LV) function, myocardial viability, and infarct resorption. Histologic evaluation of neovascularization was then performed.
RESULTS: MR fluoroscopic guidance of injectates was successful in both groups. Treated animals with chronic, but not those with acute, infarction showed the following differences compared with control animals: (a) steeper mean maximum upslope perfusion (200 sec(-1) +/- 32 vs 117 sec(-1) +/- 15, P = .02), (b) higher peak signal intensity (1667 arbitrary units +/- 100 vs 1132 arbitrary units +/- 80, P = .002), (c) increased ejection fraction (from 27.9% +/- 1.2 to 35.3% +/- 1.6, P = .001), (d) smaller infarction size (as a percentage of LV mass) at MR imaging (8.5% +/- 0.9 vs 11.3% +/- 0.9, P = .048) and triphenyltetrazolium chloride staining (9.4% +/- 1.5 vs 12.7% +/- 0.4, P = .05), and (e) higher vascular density (as number of vessels per square millimeter) at the border (430 +/- 117 vs 286 +/- 19, P = .0001) and core (307 +/- 112 vs 108 +/- 17, P = .0001).
CONCLUSION: The validity of plasmid VEGF gene delivered with MR fluoroscopic guidance into occlusive infarction was confirmed by neovascularization associated with improved perfusion, LV function, and infarct resorption.
Maythem Saeed; Alastair Martin; Alexis Jacquier; Matthew Bucknor; David Saloner; Loi Do; Philip Ursell; Hua Su; Yuet W Kan; Charles B Higgins
Related Documents :
6213214 - Isolated right ventricular infarction with massive dilation: acquired uhl's disease?
2452314 - Effect of digoxin on the extent of injury and the severity of arrhythmias during acute ...
2923244 - Subendocardial infarction produces epicardial parasympathetic denervation in canine lef...
9854664 - Thoracic epidural anesthesia does not affect functional recovery from myocardial stunni...
25248814 - Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure ...
663694 - Left ventricular aneurysms caused by blunt chest trauma.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-09-09
Journal Detail:
Title:  Radiology     Volume:  249     ISSN:  1527-1315     ISO Abbreviation:  Radiology     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-21     Completed Date:  2008-11-18     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  0401260     Medline TA:  Radiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  560-71     Citation Subset:  AIM; IM    
Copyright Information:
(c) RSNA, 2008.
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94134-0628, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Contrast Media / administration & dosage
Coronary Occlusion / drug therapy*
Genetic Therapy / methods*
Magnetic Resonance Imaging, Interventional / methods*
Meglumine / administration & dosage
Organometallic Compounds / administration & dosage
Vascular Endothelial Growth Factor A / genetics,  pharmacology*
Grant Support
Reg. No./Substance:
0/Contrast Media; 0/Organometallic Compounds; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/gadoterate meglumine; 6284-40-8/Meglumine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Off-resonance angiography: a new method to depict vessels--phantom and rabbit studies.
Next Document:  Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor bloo...